Trial
NCT02890381
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
—
Condition
Respiratory Syncytial Virus Infections
Intervention
RSV LID cp ΔM2-2 Vaccine
Why stopped
Interim data indicated this vaccine will not meet the protocol criteria for a good vaccine candidate.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-05